The basis of the discovery process for a new pharmaceutical product

• Authors: Veselin Dickov
• Languages of publication: EN

Abstracts

EN

The basis of the discovery process for a new pharmaceutical product is in understanding the mechanism of action of a particular disease or processes in the organism related to the disease and/or its symptoms. The essence of a pharmaceutical is in the active ingredient capable of affecting processes within the organism beneficially. The discovery process includes a particular sequence of activities of various profiles of experts, about which various authors agree. The history of pharmaceutical industry (and pharmacy) is measured from one discovery of an innovative drug or approach to treatment of a particular disease to the next one. The cost of pharmaceutical products is one of the key causes of controversy related to this industry. Numerous cultures have proverbs expressing the opinion that health is priceless or that health is the greatest wealth. What if health does have a price? One of the basic premises of marketing is that price should reflect consumer value.

Keywords

EN

Pharmaceutical market; New drug development; Pricing regulations; The cost of pharmaceutical products

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 6
• Pages: 691-699

Dates

published

1 - 12 - 2012

online

11 - 10 - 2012

Contributors

author

Veselin Dickov

• Faculty of International Management, European University, 11 000, Belgrade, Serbia

References

• [1] Dickov V., Kuzman B. (2011) ”Analyzing Pharmaceutical Industry” National Journal of Physiology, Pharmacy and Pharmacology. NJPPP.; 1(1): pp. 1–8
• [2] Suhrcke M, McKee M, Sauto Arce R. Tsolova S. and Mortensen J. (2005): The contribution of health to the economy in the European Union. European Commission. Office for Official Publications of the European Communities. Luxembourg, No 3, pp. 373–377
• [3] Dickov V. Dickov A. Milicevic B., (2010) “Freedom from disease - Health protection system in Serbia - management approach”, International Journal, Total Quality Management & Excellence, Vol. 38, No. 2, pp.119–126
• [4] Franklin J. Carter, Ravindra Chitturi, Segmentation Based on Physicians Behavior(2009): Implications for Sales forecasting and Marketing-mix Strategy; Journal of Personal Selling & Sales Management, Vol.XXIX, No. 1, pp. 123–134
• [5] Gagan Bhalla, Theodoros Evgeniou, Leonard Lerer, (2004) Customer Relationship Management and Networked Healthcare in the Pharmaceutical Industry; International Journal of Medical Marketing, Vol.4, pp. 34–35 http://dx.doi.org/10.1057/palgrave.jmm.5040188[Crossref]
• [6] Gregory T. Gundlach, (2007) The American Marketing Association’s 2004 Definition of marketing: perspectives on Its Implications for Scholarship and the Role and Responsibility of marketing in Society; Journal of Public Policy & Marketing, Fall, Vol. 26(2). pp. 234–245
• [7] Jennz Darroch, Morgan P. Miles, Andrew Jardine, Ernest F. Cooke, (2004) The AMA Definition of Marketing and its Relationship to a Market Orientation: An Extension of Cooke, Rayburn, & Abercrombie; Journal of Marketing Theory and Practice Fall, No 1, pp. 12–15
• [8] Dickov V., Nerandjic B.and Perovic V: (2004) “Ekonomika moderna” Stilos, FTN, Novi Sad 2004. Vol 1, No 1, pp. 9–23
• [9] Sandier S., et al: (2004) Health Care Systems in Transition, Edited by: Sarah Thomson and Elias Mossialos, WHO - Regional Office for Europe, No 1, pp.45–51
• [10] Alfred D. Chandler Jr., (2005) Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries; Harvard University Press, London, UK, Vol.1, No 1, pp. 36–39
• [11] Fran Hawthorne, (2005) Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat; John Wiley & Sons, Inc., Hoboken, New Jersey, USA Vol.3 No 3, pp. 56–67
• [12] Frank Bradley, (2009) Strategic Marketing In the Customer Driven Organization; John Wiley and Sons, Chichester, West Sussex, England, No. 3, pp. 89–90
• [13] Dickov V., Kuzman B. “The Promotion of Pharmaceutical Products”, Materia Socio Medica 2011. Volume 23. Number 1. Pp. 48–59
• [14] Henry Mintzberg, James Brian Quinn, Sumantra Ghoshal, (2010) The Strategy Process; Prentice Hall Europe, Hertfordshire, UK, No. 1, pp.76–78
• [15] Kate Gillespie, Jeannet Jean-Pierre, Hennessey H. David, (2009) Global Marketing; Houghton Mifflin Company, Boston, USA, Vol. 1, No 3, pp. 60–62
• [16] Emira Kahrovic “Chemical feature of inorganic compounds as anticancer agents” HealthMED - Volume 5. Number 5. 2011. pp.1112–1117
• [17] Dickov A., Vuckovic N., Dickov V., S. Martinović- Mitrović “Post traumatic stress disorder (PTSD) after traffic accident - PTSD and traffic accidents”. HealthMED - Volume 4/Number 4/Supplement 1/2010. pp.1037–1043
• [18] Orville C. Walker Jr., Harper W. Boyd Jr., John Mullins, Jean-Claude Larreche, (2010) Marketing Strategy: A Decision-Focused Approach; McGraw-Hill Irwin, New York, Vol.1, pp. 223–229
• [19] Robert F. Dyer, Ernest H. Forman, An Analitic Approach to Marketing Decisions; Prentice Hall, New Yersey, USA, 1991. pp.107–110
• [20] Dickov V., Mitrovic D., Kuzman B., HEALTHY IN TRANSITION - Private or government health institutions - Patient choice,, Case Study Case Rep. 2011; 1 pp. 61–73
• [21] Tom Blackett, Rebecca Robins, Brand Medicine, The Role of Branding in the Pharmaceutical Industry; Palgrave, New York, USA, 2002 pp.98–103
• [22] William O. Bearden, Thomas N. Ingram, Raymond W. Longest J.B. Rakich J.S. and Darr K. Managing: Health Service Organization and Systems, London (1993) pp. 234–256

Identifiers

DOI

10.2478/s11536-012-0080-2